A Phase 3 interventional study of Brexpiprazole in Irritability Associated With Autism Spectrum Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 28 sites in United States. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-05-30.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Autistic Disorder by Otsuka Holdings Co., Ltd. — none open to participants now, none under way, none of them phase 3. Autistic Disorder · Otsuka Holdings Co., Ltd..
Among the 11 studies in Autistic Disorder by Otsuka Holdings Co., Ltd., this one is the 7th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2020, is one of 8 in phase 3, and was the 11th registered.
1,033 studies on the registry are indexed under Autistic Disorder; 269 are open to participants now.
Browse Autistic Disorder studies →None of the 11 studies in Autistic Disorder by Otsuka Holdings Co., Ltd. is open now. The open studies under Autistic Disorder, anywhere →
Of the 183 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 143 (78%) stop at 75 or younger; 148 take children under 18; 56 take healthy volunteers.
This study: 5 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 95 is above the median of 49 across 813 interventional studies indexed under Autistic Disorder.
Median enrollment 105 across the 10 interventional studies, 528 across the 1 observational. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Autistic Disorder by Otsuka Holdings Co., Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the long-term safety and tolerability of brexpiprazole in children and adolescent participants, aged 5 to 17, with irritability associated with autism spectrum disorder.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received brexpiprazole based on the body weight for 26 weeks in this study. Participants with body weight \< 50 kilograms (kg), received brexpiprazole tablets orally, once daily (QD) at dose of 0.25 mg on Days 1 to 3 followed by 0.5 mg on Days 4 to 7 and 1 mg on Days 8 to 14. Based on the investigator's judgment, the dose was increased to 1 or 1.5 mg starting from Day 15 until week 26. Participants with body weight ≥ 50 kg received brexpiprazole tablet orally, QD at dose of 0.5 mg on Days 1 to 3, followed by 1.5 mg on Days 4 to 7, and 2 mg on Days 8 to 14. Based on the investigator's judgment the dose was increased to 1.5, 2, or 3 mg starting from Day 15 until week 26.
Drug: Brexpiprazole
Oral tablet; taken once daily
Also known as: OPC-34712, LuAF41156
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Graded By Severity, Serious TEAEs and Trial Discontinuation Due to TEAEs
An AE is any untoward medical occurrence in a clinical trial participant administered a medicinal product that does not necessarily have a causal relationship with the treatment. An SAE: AE that results in the appearance of (or worsening of any pre-existing) undesirable signs, symptoms, or medical conditions i.e. fatal, life-threatening, result in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, and requires inpatient hospitalization or prolongation of existing hospitalization. A TEAE is defined as an AE that started after trial drug treatment; or if the event was continuous from baseline and was worsening, serious, trial drug-related, or resulted in death, discontinuation, interruption, or reduction of trial therapy. TEAEs were graded as, Mild: Discomfort noticed, but no disruption to daily activity, Moderate: Discomfort sufficient to reduce or affect normal daily activity, and Severe: Inability to work or perform normal daily activity.
Time frame: From the first dose of study drug (in current study) up to 21 days after the last dose of study drug (up to approximately 29 weeks)
Number of Participants With Potentially Clinically Relevant Abnormalities in Vital Signs
Vital signs measurements included body weight, body temperature, systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate. Blood pressure (i.e., SBP, DBP) and heart rate were measured in the supine and standing positions after the participant had been in each position for at least 3 minutes. The participants were categorized based on the clinically relevant vital sign values as per protocol-predefined criteria. The categories with at least one participant with clinically significant value outside the normal range for vital signs are reported.
Time frame: Baseline (current study) up to Week 26
Number of Participants With Potentially Clinically Relevant Electrocardiogram (ECG) Abnormalities
Twelve-lead ECG recordings were obtained after the participant was supine and at rest for at least 5 minutes. Criteria for identifying ECG measurements of potential clinical relevance included Rate: Tachycardia (Vent ≥110 beats per minute \[bpm\]; increase ≥15bpm), Bradycardia (Vent ≤ 60bpm; decrease ≥15bpm); Rhythm: Sinus tachycardia (≥ 110bpm; an increase of ≥15 bpm), Sinus bradycardia (≤ 60bpm; a decrease of ≥15 bpm), Supraventricular premature beat (not present at baseline and present post-baseline), Conduction: Right bundle branch block (not present at baseline and present post-baseline) and ST/T Morphology: Symmetrical T-Wave Inversion (not present at baseline and present post-baseline). The categories with at least one participant with clinically relevant ECG abnormalities are reported.
Time frame: Baseline (current study) up to Week 26
Number of Participants With Potentially Clinically Relevant Laboratory Test Abnormalities
Laboratory assessments included - serum chemistry including prolactin and thyrotropin, hematology, and urinalysis. Number of participants with potentially clinically relevant laboratory test abnormalities were reported as per criteria defined in SAP. The categories with at least one participant with clinically relevant value outside the normal range for laboratory assessments are reported.
Time frame: Baseline (current study) up to Week 26
Number of Participants With Potentially Clinically Relevant Abnormal Physical Examination Values
Physical examination included measurement of height and the examination of the head, ears, eyes, nose, and throat (HEENT); thorax; abdomen; urogenital; extremities; neurological; and skin and mucosae. Participants with abnormal values, as assessed by the investigator were reported.
Time frame: Baseline (current study) up to Week 26
Number of Participants With Suicidality as Measured by Columbia-Suicide Severity Rating Scale (C-SSRS)
Suicidality as defined as at least one occurrence of suicidal ideation or suicidal behavior, was assessed using C-SSRS. The assessment included "yes" or "no" responses for 5 questions, each related to suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan) \& suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, suicide). Numeric ratings were provided for suicidal ideation: Score range of 1 (wish to be dead) to 5 (active suicidal ideation with specific plan and intent), higher total scores indicate more suicidal ideation; Suicidal behavior: Score range of 0 (no suicidal behavior) to 4 (actual suicide attempt), higher total scores indicate more suicidal behavior. Number of participants with at least one occurrence of suicidal ideation or suicidal behavior was reported.
Time frame: Baseline (current study) up to Week 26
Change From Baseline in Simpson Angus Scale (SAS) Total Score at Week 2
SAS was used to evaluate extrapyramidal symptoms (EPS). The SAS consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Severity of each item was rated on a 5-point Likert scale, with a score of 0 (absence of symptoms) to 4 (severe condition). The SAS total score is the sum of the scores of all 10 items, ranging from 0 to 40 where a higher score indicates a severe condition. Negative change from baseline indicates absence of symptoms.
Time frame: Baseline and Week 2
Change From Baseline in SAS Total Score at Week 14
SAS was used to evaluate extrapyramidal symptoms (EPS). The SAS consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Severity of each item was rated on a 5-point Likert scale, with a score of 0 (absence of symptoms) to 4 (severe condition). The SAS total score is the sum of the scores of all 10 items, ranging from 0 to 40 where a higher score indicates a severe condition. Negative change from baseline indicates absence of symptoms.
Time frame: Baseline and Week 14
Change From Baseline in SAS Total Score at Week 26
SAS was used to evaluate extrapyramidal symptoms (EPS). The SAS consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Severity of each item was rated on a 5-point Likert scale, with a score of 0 (absence of symptoms) to 4 (severe condition). The SAS total score is the sum of the scores of all 10 items, ranging from 0 to 40 where a higher score indicates a severe condition. Negative change from baseline indicates absence of symptoms.
Time frame: Baseline and Week 26
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score at Week 2
The AIMS is a 12-item scale. The first 10 items are rated on a Likert 5-point scale from 0 to 4 (0 = best, 4 = worst). An item score of 0, depending on specific item, means either "no abnormal Involuntary movement (AIM)" or "no incapacitation due to AIM" or "no awareness of AIM". An item score of 4 means either "severe AIM" or "severe incapacitation due to AIM" or "being aware of, and severe distress caused by AIM". Items 11 and 12 are related to dental status, taking dichotomous response: 0 = no and 1 = yes. AIMS movement score is the sum of the ratings for the first seven items with possible total scores of 0 to 28, where a higher score indicates a severe condition.
Time frame: Baseline and Week 2
Change From Baseline in AIMS Total Score at Week 14
The AIMS is a 12-item scale. The first 10 items are rated on a Likert 5-point scale from 0 to 4 (0 = best, 4 = worst). An item score of 0, depending on specific item, means either "no abnormal Involuntary movement (AIM)" or "no incapacitation due to AIM" or "no awareness of AIM". An item score of 4 means either "severe AIM" or "severe incapacitation due to AIM" or "being aware of, and severe distress caused by AIM". Items 11 and 12 are related to dental status, taking dichotomous response: 0 = no and 1 = yes. AIMS movement score is the sum of the ratings for the first seven items with possible total scores of 0 to 28, where a higher score indicates a severe condition.
Time frame: Baseline and Week 14
Change From Baseline in AIMS Total Score at Week 26
The AIMS is a 12-item scale. The first 10 items are rated on a Likert 5-point scale from 0 to 4 (0 = best, 4 = worst). An item score of 0, depending on specific item, means either "no abnormal Involuntary movement (AIM)" or "no incapacitation due to AIM" or "no awareness of AIM". An item score of 4 means either "severe AIM" or "severe incapacitation due to AIM" or "being aware of, and severe distress caused by AIM". Items 11 and 12 are related to dental status, taking dichotomous response: 0 = no and 1 = yes. AIMS movement score is the sum of the ratings for the first seven items with possible total scores of 0 to 28, where a higher score indicates a severe condition. A negative change from baseline indicates less symptoms.
Time frame: Baseline and Week 26
Change From Baseline in Barnes Akathisia Rating Scale (BARS) Score at Week 2
The BARS consists of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the participant, subjective distress due to akathisia, and global clinical assessment of akathisia. The first 3 items were rated on a 4-point Likert scale, with a score of 0 (absence of symptoms) to 3 (severe condition) and the global clinical assessment was rated on a 6-point scale, with a score of 0 (absence of symptoms) to 5 (severe akathisia). Total score is the sum of the scores of all 4 items, ranging from 0 to 14. Lower scores indicate less symptoms.
Time frame: Baseline and Week 2
Change From Baseline in BARS Score at Week 14
The BARS consists of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the participant, subjective distress due to akathisia, and global clinical assessment of akathisia. The first 3 items were rated on a 4-point Likert scale, with a score of 0 (absence of symptoms) to 3 (severe condition) and the global clinical assessment was rated on a 6-point scale, with a score of 0 (absence of symptoms) to 5 (severe akathisia). Total score is the sum of the scores of all 4 items, ranging from 0 to 14. Lower scores indicate less symptoms and negative change from baseline indicate less symptoms.
Time frame: Baseline and Week 14
Change From Baseline in BARS Score at Week 26
The BARS consists of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the participant, subjective distress due to akathisia, and global clinical assessment of akathisia. The first 3 items were rated on a 4-point Likert scale, with a score of 0 (absence of symptoms) to 3 (severe condition) and the global clinical assessment was rated on a 6-point scale, with a score of 0 (absence of symptoms) to 5 (severe akathisia). Total score is the sum of the scores of all 4 items, ranging from 0 to 14. Lower scores indicate less symptoms and negative change from baseline indicate less symptoms.
Time frame: Baseline and Week 26
Percentage of Participants With Potentially Clinically Relevant Changes in Weight up to Week 14
Percentage of participants who had significant weight gain (≥ 7% increase in body weight relative to baseline) and significant weight loss (≥ 7% decrease in body weight relative to baseline) were reported.
Time frame: Baseline up to Week 14
Percentage of Participants With Potentially Clinically Relevant Changes in Weight up to Week 26
Percentage of participants who had significant weight gain (≥ 7% increase in body weight relative to baseline) and significant weight loss (≥ 7% decrease in body weight relative to baseline) were reported.
Time frame: Baseline up to Week 26
Time to Discontinuation Due to AE
The time to discontinuation due to AE was defined as the total number of days between the enrolment date and the discontinuation date. The time to discontinuation was analyzed using the Kaplan Meier curve.
Time frame: Baseline (in current study) up to 21 days post last dose of study drug (up to approximately 29 weeks)
Mean Change From Baseline to Week 26 in Aberrant Behavior Checklist - Irritability (ABC-I) Subscale Score
The ABC is parent-reported rating scale designed to assess treatment effects on problem behavior in participants with intellectual disabilities. The ABC scale has 58 items, which divide into 5 subscales as follows:(1) Irritability, Agitation; (2) Lethargy, Social Withdrawal; (3) Stereotypic Behavior; (4) Hyperactivity, Noncompliance; and (5) Inappropriate Speech. Each of the 58 ABC items is rated on a 4-point scale (0 = not at all a problem; 1=the behavior is a problem, but slight in degree; 2=problem is moderately serious; 3=problem is severe in degree). The Irritability subscale (ABC-I) measures emotional and behavioral symptoms of ASD, including aggression toward others, deliberate self-injuriousness, temper tantrums, \& quickly changing moods. ABC-I total score is the sum of the ratings over 15 ABC items. Individual scores were summed, thus the ABC-I total score ranges from 0 to 45. Higher scores represent the worst condition. Negative change from baseline indicates less symptoms.
Time frame: Baseline (current study), Week 26
Mean Change From Baseline to Week 26 in Clinical Global Impression - Severity (CGI-S) Scale Score
The CGI-S scale is a clinician-rated assessment that evaluates the severity of a participant's condition with a focus on symptoms of irritability on a 7-point scale. The investigator (or rater) answered the following question: "Considering your total clinical experience with this particular population, how ill was the participant at this time with regard to symptoms of irritability?" Response choices were 0 = not assessed; 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients. The total score ranges from 0 to 7, where higher scores indicate worse condition. A negative change from baseline indicates less symptoms.
Time frame: Baseline (current study), Week 26
Participants with irritability associated with autism spectrum disorder (ASD) were enrolled in the study at sites in the United States from 23 January 2020 to 16 March 2023.
| Milestone | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| Started | 49 | 46 |
| Safety sample | 49 | 46 |
| Efficacy sample | 48 | 46 |
| Completed | 39 | 31 |
| Not completed | 10 | 15 |
| Withdrew: Adverse event | 2 | 4 |
| Withdrew: Lack of efficacy | 0 | 2 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Withdrawal by caregiver | 5 | 6 |
| Withdrew: Reason not specified | 0 | 1 |
An AE is any untoward medical occurrence in a clinical trial participant administered a medicinal product that does not necessarily have a causal relationship with the treatment. An SAE: AE that results in the appearance of (or worsening of any pre-existing) undesirable signs, symptoms, or medical conditions i.e. fatal, life-threatening, result in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, and requires inpatient hospitalization or prolongation of existing hospitalization. A TEAE is defined as an AE that started after trial drug treatment; or if the event was continuous from baseline and was worsening, serious, trial drug-related, or resulted in death, discontinuation, interruption, or reduction of trial therapy. TEAEs were graded as, Mild: Discomfort noticed, but no disruption to daily activity, Moderate: Discomfort sufficient to reduce or affect normal daily activity, and Severe: Inability to work or perform normal daily activity.
| Participants | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| Participants With TEAEs | 23 | 24 |
| Participants With Mild TEAEs | 15 | 19 |
| Participants With Moderate TEAEs | 11 | 12 |
| Participants With Severe TEAEs | 2 | 2 |
| Participants With Serious TEAEs | 2 | 1 |
| Participants With Trial Discontinuations due to TEAEs | 2 | 4 |
Vital signs measurements included body weight, body temperature, systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate. Blood pressure (i.e., SBP, DBP) and heart rate were measured in the supine and standing positions after the participant had been in each position for at least 3 minutes. The participants were categorized based on the clinically relevant vital sign values as per protocol-predefined criteria. The categories with at least one participant with clinically significant value outside the normal range for vital signs are reported.
| Participants | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| SBP Standing (mmHg): High | 4 | 5 |
| SBP Supine (mmHg): High | 1 | 5 |
| DBP Standing (mmHg): Low | 0 | 1 |
| DBP Standing (mmHg): High | 2 | 1 |
| DBP Supine (mmHg): Low | 1 | 1 |
| DBP Supine (mmHg): High | 1 | 3 |
| Heart Rate Standing (beats/min): High | 10 | 4 |
| Heart Rate Supine (beats/min): Low | 1 | 0 |
| Heart Rate Supine (beats/min): High | 3 | 1 |
| Body Temperature | 0 | 0 |
Twelve-lead ECG recordings were obtained after the participant was supine and at rest for at least 5 minutes. Criteria for identifying ECG measurements of potential clinical relevance included Rate: Tachycardia (Vent ≥110 beats per minute \[bpm\]; increase ≥15bpm), Bradycardia (Vent ≤ 60bpm; decrease ≥15bpm); Rhythm: Sinus tachycardia (≥ 110bpm; an increase of ≥15 bpm), Sinus bradycardia (≤ 60bpm; a decrease of ≥15 bpm), Supraventricular premature beat (not present at baseline and present post-baseline), Conduction: Right bundle branch block (not present at baseline and present post-baseline) and ST/T Morphology: Symmetrical T-Wave Inversion (not present at baseline and present post-baseline). The categories with at least one participant with clinically relevant ECG abnormalities are reported.
| Participants | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| Rate: Tachycardia | 1 | 2 |
| Rate: Bradycardia | 1 | 0 |
| Rhythm: Sinus Tachycardia | 1 | 2 |
| Rhythm: Sinus Bradycardia | 1 | 0 |
| Rhythm: Supraventricular Premature Beat | 1 | 0 |
| Conduction: Right Bundle Branch Block | 0 | 1 |
| ST/T Morphology: Symmetrical T-Wave Inversion | 0 | 1 |
Laboratory assessments included - serum chemistry including prolactin and thyrotropin, hematology, and urinalysis. Number of participants with potentially clinically relevant laboratory test abnormalities were reported as per criteria defined in SAP. The categories with at least one participant with clinically relevant value outside the normal range for laboratory assessments are reported.
| Participants | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| Activated Partial Thromboplastin Time (sec): High | 6 | 2 |
| Alanine Aminotransferase (U/L): High | 0 | 2 |
| Aspartate Aminotransferase (U/L): High | 0 | 1 |
| Bicarbonate (mEq/L): Low | 14 | 15 |
| Bilirubin (mg/dL): Low | 10 | 8 |
| Bilirubin (mg/dL): High | 0 | 1 |
| Calcium (mg/dL): Low | 0 | 1 |
| Chloride (mEq/L): High | 2 | 0 |
| Cortisol (ug/dL): Low | 7 | 9 |
| Creatinine (mg/dL): High | 1 | 0 |
| Glucose (mg/dL): Low | 0 | 1 |
| Glucose (mg/dL): High | 1 | 0 |
| Potassium (mEq/L): High | 1 | 3 |
| Sodium (mEq/L): High | 2 | 0 |
| Eosinophils/Leukocytes (%): High | 2 | 3 |
| Hematocrit (%): Low | 0 | 1 |
| Hematocrit (%): High | 1 | 0 |
| Hemoglobin (g/dL): Low | 1 | 0 |
| Hemoglobin A1C (%): High | 2 | 4 |
| Leukocytes (10^9/L): Low | 6 | 2 |
| Leukocytes (10^9/L): High | 0 | 1 |
| Neutrophils (10^9/L): High | 0 | 2 |
| Neutrophils/Leukocytes (%): Low | 8 | 2 |
| Neutrophils/Leukocytes (%): High | 0 | 2 |
| Platelets (10^9/L): High | 1 | 1 |
| Prothrombin Intl. Normalized Ratio: High | 5 | 2 |
| Prothrombin Time (sec): High | 3 | 2 |
| Protein, Urine: Low | 12 | 11 |
| Protein, Urine: High | 10 | 11 |
| Prolactin (ng/mL): Low | 3 | 4 |
| Prolactin (ng/mL): High | 1 | 2 |
| Thyrotropin (uIU/mL): High | 2 | 0 |
Physical examination included measurement of height and the examination of the head, ears, eyes, nose, and throat (HEENT); thorax; abdomen; urogenital; extremities; neurological; and skin and mucosae. Participants with abnormal values, as assessed by the investigator were reported.
| Participants | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| Number of Participants With Potentially Clinically Relevant Abnormal Physical Examination Values | 6 | 4 |
Suicidality as defined as at least one occurrence of suicidal ideation or suicidal behavior, was assessed using C-SSRS. The assessment included "yes" or "no" responses for 5 questions, each related to suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan) \& suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, suicide). Numeric ratings were provided for suicidal ideation: Score range of 1 (wish to be dead) to 5 (active suicidal ideation with specific plan and intent), higher total scores indicate more suicidal ideation; Suicidal behavior: Score range of 0 (no suicidal behavior) to 4 (actual suicide attempt), higher total scores indicate more suicidal behavior. Number of participants with at least one occurrence of suicidal ideation or suicidal behavior was reported.
| Participants | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| Number of Participants With Suicidality as Measured by Columbia-Suicide Severity Rating Scale (C-SSRS) | 4 | 2 |
SAS was used to evaluate extrapyramidal symptoms (EPS). The SAS consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Severity of each item was rated on a 5-point Likert scale, with a score of 0 (absence of symptoms) to 4 (severe condition). The SAS total score is the sum of the scores of all 10 items, ranging from 0 to 40 where a higher score indicates a severe condition. Negative change from baseline indicates absence of symptoms.
| score on a scale | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| Change From Baseline in Simpson Angus Scale (SAS) Total Score at Week 2 | -0.0 ± 0.5 | 0.0 ± 0.5 |
SAS was used to evaluate extrapyramidal symptoms (EPS). The SAS consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Severity of each item was rated on a 5-point Likert scale, with a score of 0 (absence of symptoms) to 4 (severe condition). The SAS total score is the sum of the scores of all 10 items, ranging from 0 to 40 where a higher score indicates a severe condition. Negative change from baseline indicates absence of symptoms.
| score on a scale | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| Change From Baseline in SAS Total Score at Week 14 | -0.1 ± 0.7 | 0.2 ± 0.6 |
SAS was used to evaluate extrapyramidal symptoms (EPS). The SAS consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Severity of each item was rated on a 5-point Likert scale, with a score of 0 (absence of symptoms) to 4 (severe condition). The SAS total score is the sum of the scores of all 10 items, ranging from 0 to 40 where a higher score indicates a severe condition. Negative change from baseline indicates absence of symptoms.
| score on a scale | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| Change From Baseline in SAS Total Score at Week 26 | -0.1 ± 0.9 | -0.0 ± 0.2 |
The AIMS is a 12-item scale. The first 10 items are rated on a Likert 5-point scale from 0 to 4 (0 = best, 4 = worst). An item score of 0, depending on specific item, means either "no abnormal Involuntary movement (AIM)" or "no incapacitation due to AIM" or "no awareness of AIM". An item score of 4 means either "severe AIM" or "severe incapacitation due to AIM" or "being aware of, and severe distress caused by AIM". Items 11 and 12 are related to dental status, taking dichotomous response: 0 = no and 1 = yes. AIMS movement score is the sum of the ratings for the first seven items with possible total scores of 0 to 28, where a higher score indicates a severe condition.
| score on a scale | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score at Week 2 | 0.0 ± 0.00 | 0.14 ± 1.08 |
The AIMS is a 12-item scale. The first 10 items are rated on a Likert 5-point scale from 0 to 4 (0 = best, 4 = worst). An item score of 0, depending on specific item, means either "no abnormal Involuntary movement (AIM)" or "no incapacitation due to AIM" or "no awareness of AIM". An item score of 4 means either "severe AIM" or "severe incapacitation due to AIM" or "being aware of, and severe distress caused by AIM". Items 11 and 12 are related to dental status, taking dichotomous response: 0 = no and 1 = yes. AIMS movement score is the sum of the ratings for the first seven items with possible total scores of 0 to 28, where a higher score indicates a severe condition.
| score on a scale | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| Change From Baseline in AIMS Total Score at Week 14 | 0.0 ± 0.00 | 0.16 ± 1.15 |
The AIMS is a 12-item scale. The first 10 items are rated on a Likert 5-point scale from 0 to 4 (0 = best, 4 = worst). An item score of 0, depending on specific item, means either "no abnormal Involuntary movement (AIM)" or "no incapacitation due to AIM" or "no awareness of AIM". An item score of 4 means either "severe AIM" or "severe incapacitation due to AIM" or "being aware of, and severe distress caused by AIM". Items 11 and 12 are related to dental status, taking dichotomous response: 0 = no and 1 = yes. AIMS movement score is the sum of the ratings for the first seven items with possible total scores of 0 to 28, where a higher score indicates a severe condition. A negative change from baseline indicates less symptoms.
| score on a scale | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| Change From Baseline in AIMS Total Score at Week 26 | 0.00 ± 0.00 | -0.04 ± 0.19 |
The BARS consists of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the participant, subjective distress due to akathisia, and global clinical assessment of akathisia. The first 3 items were rated on a 4-point Likert scale, with a score of 0 (absence of symptoms) to 3 (severe condition) and the global clinical assessment was rated on a 6-point scale, with a score of 0 (absence of symptoms) to 5 (severe akathisia). Total score is the sum of the scores of all 4 items, ranging from 0 to 14. Lower scores indicate less symptoms.
| score on a scale | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| Change From Baseline in Barnes Akathisia Rating Scale (BARS) Score at Week 2 | 0.02 ± 0.26 | 0.05 ± 0.30 |
The BARS consists of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the participant, subjective distress due to akathisia, and global clinical assessment of akathisia. The first 3 items were rated on a 4-point Likert scale, with a score of 0 (absence of symptoms) to 3 (severe condition) and the global clinical assessment was rated on a 6-point scale, with a score of 0 (absence of symptoms) to 5 (severe akathisia). Total score is the sum of the scores of all 4 items, ranging from 0 to 14. Lower scores indicate less symptoms and negative change from baseline indicate less symptoms.
| score on a scale | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| Change From Baseline in BARS Score at Week 14 | -0.05 ± 0.22 | 0.05 ± 0.40 |
The BARS consists of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the participant, subjective distress due to akathisia, and global clinical assessment of akathisia. The first 3 items were rated on a 4-point Likert scale, with a score of 0 (absence of symptoms) to 3 (severe condition) and the global clinical assessment was rated on a 6-point scale, with a score of 0 (absence of symptoms) to 5 (severe akathisia). Total score is the sum of the scores of all 4 items, ranging from 0 to 14. Lower scores indicate less symptoms and negative change from baseline indicate less symptoms.
| score on a scale | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| Change From Baseline in BARS Score at Week 26 | 0.00 ± 0.24 | -0.04 ± 0.19 |
Percentage of participants who had significant weight gain (≥ 7% increase in body weight relative to baseline) and significant weight loss (≥ 7% decrease in body weight relative to baseline) were reported.
| percentage of participants | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| Weight Gain >= 7% | 45.0 | 48.6 |
| Weight Loss >= 7% | 0.0 | 0.0 |
Percentage of participants who had significant weight gain (≥ 7% increase in body weight relative to baseline) and significant weight loss (≥ 7% decrease in body weight relative to baseline) were reported.
| percentage of participants | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| Weight Gain >= 7% | 71.8 | 76.7 |
| Weight Loss >= 7% | 0.0 | 3.3 |
The time to discontinuation due to AE was defined as the total number of days between the enrolment date and the discontinuation date. The time to discontinuation was analyzed using the Kaplan Meier curve.
| days | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| Time to Discontinuation Due to AE | 83 (14 to 152) | 113 (54 to 140) |
The ABC is parent-reported rating scale designed to assess treatment effects on problem behavior in participants with intellectual disabilities. The ABC scale has 58 items, which divide into 5 subscales as follows:(1) Irritability, Agitation; (2) Lethargy, Social Withdrawal; (3) Stereotypic Behavior; (4) Hyperactivity, Noncompliance; and (5) Inappropriate Speech. Each of the 58 ABC items is rated on a 4-point scale (0 = not at all a problem; 1=the behavior is a problem, but slight in degree; 2=problem is moderately serious; 3=problem is severe in degree). The Irritability subscale (ABC-I) measures emotional and behavioral symptoms of ASD, including aggression toward others, deliberate self-injuriousness, temper tantrums, \& quickly changing moods. ABC-I total score is the sum of the ratings over 15 ABC items. Individual scores were summed, thus the ABC-I total score ranges from 0 to 45. Higher scores represent the worst condition. Negative change from baseline indicates less symptoms.
| score on a scale | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| Mean Change From Baseline to Week 26 in Aberrant Behavior Checklist - Irritability (ABC-I) Subscale Score | -5.47 ± 8.06 | -7.00 ± 8.36 |
The CGI-S scale is a clinician-rated assessment that evaluates the severity of a participant's condition with a focus on symptoms of irritability on a 7-point scale. The investigator (or rater) answered the following question: "Considering your total clinical experience with this particular population, how ill was the participant at this time with regard to symptoms of irritability?" Response choices were 0 = not assessed; 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients. The total score ranges from 0 to 7, where higher scores indicate worse condition. A negative change from baseline indicates less symptoms.
| score on a scale | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| Mean Change From Baseline to Week 26 in Clinical Global Impression - Severity (CGI-S) Scale Score | -0.78 ± 0.99 | -0.68 ± 0.94 |
Collected over From the first dose of study drug (in current study) up to 21 days after the last dose of study drug (up to approximately 29 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Prior Brexpiprazole | 0/49 (0%) | 2/49 (4.1%) | 17/49 (34.7%) |
| Prior Placebo | 0/46 (0%) | 1/46 (2.2%) | 11/46 (23.9%) |
| Event | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| Affective DisorderPsychiatric disorders | 0/49 | 1/46 |
| DyskinesiaNervous system disorders | 1/49 | 0/46 |
| Suicidal IdeationPsychiatric disorders | 1/49 | 0/46 |
| Event | Prior Brexpiprazole | Prior Placebo |
|---|---|---|
| Weight IncreasedInvestigations | 5/49 | 8/46 |
| SomnolenceNervous system disorders | 5/49 | 1/46 |
| Increased AppetiteMetabolism and nutrition disorders | 2/49 | 4/46 |
| Viral InfluenzaInfections and infestations | 4/49 | 0/46 |
| GastroenteritisInfections and infestations | 3/49 | 0/46 |
| IrritabilityPsychiatric disorders | 3/49 | 0/46 |
Enrolled Sample included participants who completed the double-blind treatment period of the parent study 331-201-00148 (NCT04174365) and who gave consent/assent for participation into this open-label study and who also met all the eligibility criteria for this study.
| Age, Continuous(years) | Prior Brexpiprazole | Prior Placebo | Total |
|---|---|---|---|
| Mean | 10.0 ± 3.1 | 10.0 ± 3.1 | 10.0 ± 3.1 |
| Sex: Female, Male(Participants) | Prior Brexpiprazole | Prior Placebo | Total |
|---|---|---|---|
| Female | 4 | 8 | 12 |
| Male | 45 | 38 | 83 |
| Ethnicity (NIH/OMB)(Participants) | Prior Brexpiprazole | Prior Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 8 | 14 |
| Not Hispanic or Latino | 43 | 38 | 81 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Prior Brexpiprazole | Prior Placebo | Total |
|---|---|---|---|
| Race — White | 37 | 38 | 75 |
| Race — Black or African American | 8 | 2 | 10 |
| Race — Asian | 1 | 3 | 4 |
| Race — Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Race — Other | 3 | 2 | 5 |
| Weight(kilogram (kg)) | Prior Brexpiprazole | Prior Placebo | Total |
|---|---|---|---|
| Mean | 41.6 ± 17.9 | 44.2 ± 18.3 | 42.9 ± 18.1 |
| Simpson Angus Scale (SAS) Score(score on a scale) | Prior Brexpiprazole | Prior Placebo | Total |
|---|---|---|---|
| Mean | 0.4 ± 1.9 | 0.2 ± 0.6 | 0.3 ± 1.4 |
| Abnormal Involuntary Movement Scale (AIMS) Total Score(score on a scale) | Prior Brexpiprazole | Prior Placebo | Total |
|---|---|---|---|
| Mean | 0.06 ± 0.32 | 0.02 ± 0.15 | 0.04 ± 0.25 |
| Barnes Akathisia Rating Scale (BARS) Score(score on a scale) | Prior Brexpiprazole | Prior Placebo | Total |
|---|---|---|---|
| Mean | 0.04 ± 0.20 | 0.09 ± 0.46 | 0.06 ± 0.35 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com
Data sharing details ↗ · clinical-trials.otsuka.com
Ran from Jan 2020 to primary completion in Mar 2023, 37 months.
Results were first posted in May 2024, 1 year 2 months after primary completion.
Of 15 phase 3 interventional studies under Autistic Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 37 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →